Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sarepta Sinks On Mixed DMD Gene Therapy Study

Blames 'Bad Luck In Randomization Process'

Executive Summary

Any time advantage Sarepta's Duchenne muscular dystrophy gene therapy may have had over rivals, notably Pfizer, has disappeared after SRP-9001 failed to significantly improve muscle function in a closely watched trial.

You may also be interested in...



Sarepta Leapfrogs Pfizer In The US, Launching DMD Gene Therapy Pivotal Trial

The company has initiated the first pivotal double-blind gene therapy trial in DMD in the US in a tight race with Pfizer.

Chasing Pfizer, Sarepta Prepares To Launch Pivotal Duchenne Gene Therapy Trial

Sarepta believes it is still very much in the running with its gene therapy but is playing down talk of an accelerated approval based on biomarker data.

Pfizer DMD Gene Therapy Phase III Trial Stalled In US After FDA Questions On Potency Assays

Pfizer disclosed that a Phase III trial for the gene therapy has been unable to start in the US because of questions from the FDA, even while enrollment in 15 sites outside the US is under way.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143598

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel